Financial Gravity Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Financial Gravity Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-21	Closed	-$342	–	1641
2024 Q1	$342	Buy	+21	New	+$316	﹤0.01%	1489
2023 Q3	–	Sell	-13	Closed	-$834	–	1350
2023 Q2	$834	Sell	13 -4	-24%	-$58	﹤0.01%	858
2023 Q1	$2.27K	Sell	17 -2	-11%	-$33	0.07%	281
2022 Q4	$990	Buy	+19	New	+$293	0.01%	671

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Financial Gravity Asset Management's CPRX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 21 shares — an estimated $342 sold.

Financial Gravity Asset Management first reported a position in CPRX in Q4 2022 and held it in 4 quarters. The position peaked at $2.27K in Q1 2023. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

Financial Gravity Asset Management reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 21 Catalyst Pharmaceutical shares in Q2 2024, an estimated $342.
Financial Gravity Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 4 quarters.
Financial Gravity Asset Management's Catalyst Pharmaceutical position peaked at $2.27K in Q1 2023.
271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.